The decision by the FDA was done under accelerated approval with continued approval dependent on consequent trials verifying the clinical benefit of BLINCYTO. Read More »

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Catalyst Pharmaceuticals Inc. for Firdapse to treat myasthenia gravis (MG).e Read More »

Agreement gives Amgen global development and commercial rights to BI 836908 (AMG 420). Read More »

Adding Prolia to glucocorticoid therapy increases bone mineral density. Read More »

Will present 11 abstracts at the conference in Rome on Aug. 27-31. Read More »

Miltefosine was used to treat Naegleria fowleri infection; the teen is only the third survivor of primary amebic meningoencephalitis. Read More »

Amgen and Advaxis has announced the finalization of a worldwide agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational immunotherapy developed for the treatment of cancer. Read More »

Basal cell carcinoma nevus syndrome patients show positive results after 16 weeks in the study. Read More »

An advisory panel of the Federal Drug Administration (FDA) recently recommended approval of a medication manufactured by Amgen as a feasible alternative product to Humira, a brand created by AbbVie. Read More »

Early relapsing patients treated with Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) showed median PFS of 24.1 months. Read More »

Survey reveals that students learn best with hands-on experiments and field trips. Read More »

Kalia partners with Benzer Pharmacy to establish franchise in Tampa, Florida. Read More »

Cigna Corp. may receive additional price discounts from pharmaceutical companies should new cholesterol medications prove less effective than expected — a move marks a crucial step in a broader initiative to link the cost of medications to their efficacy. Read More »

Cigna Corp., based in Bloomfield, Connecticut, has raised the bar in pharmaceutical incentives by entering into agreements with two major suppliers that calibrate costs according to patient response, directly linking fiscal conditions to improved outcomes. Read More »

The Golden Ticket award pays for a lab bench at LabCentral for one year. Read More »

Amgen recently announced its win against Sanofi and Regeneron Pharmaceuticals. Read More »

Amgen and UCB have announced the results of the Phase 3 trial for romosozumab. Read More »

Amgen has announced that it will present 19 abstracts associated with its cardiovascular portfolio that will include new data from the evaluation of Repatha (evolocumab) at the American College of Cardiology’s 65th Annual Scientific Session (ACC 16). Read More »

Amgen and UCB have announced positive high quality results from the pivotal Phase 3 placebo-controlled study evaluatIng the efficiency and safety of romosozumab in treating men with osteoporosis (BRIDGE) trial. Read More »

Amgen has announced that its supplemental Biologics License Application (sBLA) for the extended use of Enbrel (etanercept) in the treatment of chronic severe plaque psoriasis in pediatric patients has been accepted for review by the U.S. Food and Drug Administration (FDA). Read More »